CLINICAL TRIALS PROFILE FOR OMNIPAQUE 12
✉ Email this page to a colleague
All Clinical Trials for Omnipaque 12
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00478556 ↗ | Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT | Completed | GE Healthcare | Phase 4 | 2007-08-01 | Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents. |
| NCT00478556 ↗ | Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT | Completed | University of Alabama at Birmingham | Phase 4 | 2007-08-01 | Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents. |
| NCT00587132 ↗ | Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma | Terminated | ChiRhoClin, Inc. | Phase 1/Phase 2 | 2006-11-01 | The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population. |
| NCT00587132 ↗ | Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma | Terminated | Mayo Clinic | Phase 1/Phase 2 | 2006-11-01 | The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population. |
| NCT00857792 ↗ | Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging | Completed | Astellas Pharma Inc | N/A | 2009-03-01 | The investigators goals are: 1. to develop software for quantitative volumetric analysis of myocardial perfusion from MDCT images 2. to test its ability to accurately determine the presence, location, extend and severity of perfusion abnormalities in agreement with conventional diagnostic techniques (ICA and MPI) in patients with normal and abnormal coronary arteries and/or perfusion patterns 3. to test this approach in patients undergoing vasodilator stress tests with MDCT imaging in combination with the new vasodilator stress agent Regadenoson. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Omnipaque 12
Condition Name
Clinical Trial Locations for Omnipaque 12
Trials by Country
Clinical Trial Progress for Omnipaque 12
Clinical Trial Phase
Clinical Trial Sponsors for Omnipaque 12
Sponsor Name
